CA Patent

CA3007772A1 — Modulators of complement activity

Assigned to UCB Inc · Expires 2017-06-22 · 9y expired

What this patent protects

The present invention relates to a polypeptide inhibitor of complement activity, such as C5, C5a, and membrane attack complex activity, and pharmaceutical compositions comprising said polypeptide inhibitor and a pharmaceutically acceptable excipient comprising sodium chloride at …

USPTO Abstract

The present invention relates to a polypeptide inhibitor of complement activity, such as C5, C5a, and membrane attack complex activity, and pharmaceutical compositions comprising said polypeptide inhibitor and a pharmaceutically acceptable excipient comprising sodium chloride at a concentration of from 25 mM to 100 mM and sodium phosphate at a concentration of from 10 mM to 100 mM, and uses thereof, and to uses, kits, and syringes or auto-injector devices thereof.

Drugs covered by this patent

Patent Metadata

Patent number
CA3007772A1
Jurisdiction
CA
Classification
—
Expires
2017-06-22
Drug substance claim
No
Drug product claim
No
Assignee
UCB Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.